Remote BP Monitoring in the PP Period

September 5, 2020 updated by: Leslie Moroz, Columbia University

A Remote Postpartum (PP) Blood Pressure Surveillance and Reminder System for Hypertensive Disorders of Pregnancy: A Randomized Clinical Trial

The purpose of this study is to trial remote patient monitoring (RPM) in the postpartum hypertensive population in a randomized control design, with an aim to increase the number of blood pressure measurements taken during the fragile and under-monitored postpartum period and to thereby improve postpartum blood pressure control and reduce severe morbidity and mortality. The investigators plan to compare the number of blood pressures recorded in the first 10 days postpartum between patients who have been enrolled in an RPM trial to those who are being treated with the usual care.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

Many women develop high blood pressure as a complication of pregnancy. This high blood pressure can often take many weeks to resolve, and for some women it never resolves completely. If untreated, high blood pressure of pregnancy can lead to serious consequences, such as seizure or stroke. Unfortunately, because most women are sent home from the hospital just 2-3 days after having a baby, the best way of monitoring blood pressure at home is still unknown. Most women are given a prescription for a blood pressure cuff to use at home and an appointment to see their doctor at about one week after delivery to review their blood pressures, but many women have trouble checking their blood pressures, sometimes because they have a new baby at home and sometimes for other reasons like transportation or difficult social situations. Using a Bluetooth blood pressure monitoring system might help women have better blood pressure monitoring after they are discharged from the hospital after delivery, and therefore help to prevent some of the complications that can happen because of high blood pressure related to pregnancy.

Study Type

Interventional

Enrollment (Actual)

213

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • New York
      • New York, New York, United States, 10032
        • Columbia University Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Postpartum women
  • Previous diagnosis of chronic hypertension, or antepartum diagnosis of hypertensive disorder of pregnancy (defined as documented blood pressure of ≥140 systolic or ≥90 diastolic on at least 2 occasions at least 4 hours apart)
  • At least 18 years of age
  • English or Spanish speakers

Exclusion Criteria:

  • Non-English or Spanish speakers
  • Women who are not planning on obtaining their postpartum follow up at CUIMC
  • Women who are physically unable to hold or use the tablet
  • Women who do not have a working phone
  • Provider unwilling or unable to set up escalation pathway
  • Women who reside outside of New York State
  • Hypertension diagnosed postpartum

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Usual Care
Usual care group patients will be assigned to the usual care given to patients with hypertensive disorders of pregnancy at Columbia University Irving Medical Center (CUIMC). This involves a prescription for a blood pressure cuff if they do not already have one, with which they will be asked to measure their blood pressure twice per day. They will be asked to keep a log of their blood pressure measurements and to bring that log to their next provider visit.
Experimental: Remote Patient Monitoring
Remote Patient Monitoring patients will use a Bluetooth-enabled blood pressure cuff, which will transmit blood pressure measurements via Bluetooth from the monitor to a tablet, which is able to be accessed by nurses staffing a remote clinical care center. Patients will also be prompted to answer surveys assessing symptoms of preeclampsia. The nurses will review measurements and survey results, which will be flagged in order of urgency. The measurements uploaded into the remote monitoring system will also be reviewed at the patient's next provider visit.
Bluetooth-enabled blood pressure cuff to assess whether this technology helps providers collect more data regarding their patients' blood pressures in the postpartum period.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Blood Pressure (BP) Surveillance Adherence
Time Frame: Up to 14 days from delivery hospitalization discharge
Percentage of recommended twice-daily blood pressures reported between hospital discharge and first outpatient blood pressure assessment
Up to 14 days from delivery hospitalization discharge

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Elevated Blood Pressure Percentage
Time Frame: Up to 14 days from delivery hospitalization discharge
Percentage of recorded blood pressure values at first outpatient blood pressure assessment that are elevated (>140 systolic or >90 diastolic)
Up to 14 days from delivery hospitalization discharge
Number of Participants With Outpatient BP Assessment Within 14 Days
Time Frame: Up to 14 days from delivery hospitalization discharge
Number of participants who had a documented outpatient BP assessment within 14 days of hospital discharge
Up to 14 days from delivery hospitalization discharge
Incidence of BP Elevations
Time Frame: Up to 14 days from delivery hospitalization discharge
Incidence of elevated blood pressure at outpatient blood pressure assessment
Up to 14 days from delivery hospitalization discharge
Number of Participants With Outpatient PP Assessment
Time Frame: Up to 8 weeks from delivery
Number of participants who had an outpatient postpartum (PP) assessment
Up to 8 weeks from delivery
Incidence of BP Elevations
Time Frame: Up to 8 weeks from delivery
Incidence of elevated blood pressure (BP) at the postpartum visit
Up to 8 weeks from delivery
Time to Medication Initiation
Time Frame: Up to 8 weeks from delivery
Time to initiation of antihypertensive medications (in patients who were not on medications at time of discharge)
Up to 8 weeks from delivery
Number of Participants Initiated on Antihypertensive Therapy After Hospital Discharge
Time Frame: Up to 8 weeks from delivery
Number of participants discharged from delivery hospitalization without antihypertensive therapy, who were subsequently started on antihypertensive therapy
Up to 8 weeks from delivery
Number of Participants Readmitted
Time Frame: Up to 8 weeks from delivery
Number of participants who were readmitted after delivery hospitalization discharge
Up to 8 weeks from delivery
Number of Participants With ED Visit
Time Frame: Up to 8 weeks from delivery
Number of participants who had an Emergency Department (ED) visit after delivery hospitalization discharge
Up to 8 weeks from delivery
Number of Participants Who Developed Preeclampsia-associated Complications
Time Frame: Up to 8 weeks from delivery
Number of patients who experienced preeclampsia-related morbidity (eg: stroke, seizure, posterior reversible encephalopathy syndrome (PRES) , pulmonary edema, liver function abnormality, reversible cerebral vasoconstriction syndrome (RCVS) , renal insufficiency, thrombocytopenia) after delivery hospitalization discharge.
Up to 8 weeks from delivery
Number of Participants Referred to Primary Care for Continued Blood Pressure Management
Time Frame: Up to 8 weeks from delivery
Number of participants who require a referral to primary care physicians for continued blood pressure management after being discharged from obstetric care at the postpartum visit
Up to 8 weeks from delivery
Score on the Modified Telemedicine Satisfaction and Usefulness Questionnaire (TSUQ)
Time Frame: Up to 8 weeks from delivery
The modified TSUQ is an 18-item survey that will be used to measure patient satisfaction with remote blood pressure monitoring. Individuals score each of the items based on their satisfaction, with 1=strongly disagree to 5=strongly agree. The responses would then be used to calculate a mean score on the 5-point scale, with 5 indicating the most satisfaction.
Up to 8 weeks from delivery
Change in Score on the Philips Program Survey
Time Frame: Up to 8 weeks from delivery
The Philips program start survey is a 4 question survey to gauge how patients relate to their care and their doctors prior to initiation of their blood pressure monitoring program. Individuals score each of the items based on the perception of their care, with 5 being best and 1 being worst. The responses would then be used to calculate a mean score on the 5-point scale, with 5 indicating the most satisfaction, and compared between the 2 groups. The Philips program end survey is a 6 question survey to gauge how patients related to their care and their doctors after the completion of their blood pressure monitoring program. Individuals score each of the items based on the perception of their care, with 5 being best and 1 being worst. The responses would then be used to calculate a mean score on the 5-point scale, with 5 indicating the most satisfaction, and compared between the 2 groups.
Up to 8 weeks from delivery
Communications
Time Frame: Up to 14 days post delivery hospitalization discharge
Elevated blood pressures that led to communication with an obstetric provider
Up to 14 days post delivery hospitalization discharge

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Leslie Moroz, MD, Columbia University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 9, 2018

Primary Completion (Actual)

July 28, 2019

Study Completion (Actual)

May 11, 2020

Study Registration Dates

First Submitted

October 28, 2018

First Submitted That Met QC Criteria

October 31, 2018

First Posted (Actual)

November 2, 2018

Study Record Updates

Last Update Posted (Actual)

September 28, 2020

Last Update Submitted That Met QC Criteria

September 5, 2020

Last Verified

September 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hypertensive Disorder of Pregnancy

Clinical Trials on Remote Patient Monitoring

3
Subscribe